Last edition
News about "Hansoh Pharma "
Glenmark Secures Exclusive Multi-Region Rights to Aumolertinib from Hansoh Pharma
Glenmark has entered into an exclusive licensing agreement with Hansoh Pharma to commercialise aumolertinib, a third-generation EGFR-TKI approved by the MHRA and China’s NMPA, across multiple international markets, reinforcing the company’s oncology portfolio and expansion strategy in high-growth regions.
Hansoh Pharma | 17/12/2025 | By News Bureau
Hansoh Pharma Expands Indications for Merigolix with Initiation of ART Development
Hansoh Pharma recently received approval for an IND (Investigational New Drug) application targeting ART, expanding the development area of merigolix.
Hansoh Pharma | 21/03/2025 | By Aishwarya | 299
Merck Signs Exclusive Global License Deal with Hansoh Pharma for Oral GLP-1 Receptor Agonist
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535.
Hansoh Pharma | 19/12/2024 | By Aishwarya | 480
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy